百利天恒：预计2025年净亏损11亿元 同比转亏

Core Viewpoint - Bailitianheng (688506.SH) is expected to report a net loss of approximately 1.1 billion yuan for the fiscal year 2025, a significant shift from a profit of 3.708 billion yuan in the previous year, indicating a year-on-year turnaround to loss [1] Financial Performance - The company anticipates a net profit attributable to shareholders of approximately -1.1 billion yuan for 2025, compared to a profit of 3.708 billion yuan in the same period last year, reflecting a year-on-year decline [1] - The decrease in revenue during the reporting period is primarily attributed to the recognition of intellectual property income from a previous upfront payment from BMS, which was greater than the milestone income recognized in the current reporting period [1] Research and Development - Bailitianheng has significantly increased its R&D investment, leading to a substantial year-on-year growth in R&D expenditures [1] - As of the end of the reporting period, the company has 17 innovative drugs in clinical trial stages, with 6 of these drugs undergoing global clinical trials [1] - The company is conducting over 100 innovative drug clinical trials globally [1] Product Development - The core product, iza-bren (EGFR×HER3 dual antibody ADC), has had its New Drug Application (NDA) accepted by the National Medical Products Administration (NMPA) and included in the priority review process for two indications: treatment of locally advanced or metastatic nasopharyngeal carcinoma and treatment of recurrent or metastatic esophageal squamous cell carcinoma [1]